Anthracycline Use in ERBB2-Positive Breast Cancer: It Is Time to Re-TRAIN
- PMID: 34014297
- DOI: 10.1001/jamaoncol.2021.1314
Anthracycline Use in ERBB2-Positive Breast Cancer: It Is Time to Re-TRAIN
Comment on
-
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial.JAMA Oncol. 2021 Jul 1;7(7):978-984. doi: 10.1001/jamaoncol.2021.1371. JAMA Oncol. 2021. PMID: 34014249 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous